Curing HIV: seeking to target and clear persistent infection
Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of
antiretroviral therapy (ART). To remove the stigma and burden of chronic infection …
antiretroviral therapy (ART). To remove the stigma and burden of chronic infection …
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting
B Julg, L Dee, J Ananworanich, DH Barouch, K Bar… - The lancet HIV, 2019 - thelancet.com
Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research,
seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) …
seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) …
Combination anti-HIV antibodies provide sustained virological suppression
MC Sneller, J Blazkova, JS Justement, V Shi… - Nature, 2022 - nature.com
Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV).
However, eradication of the virus in individuals with HIV has not been possible to date …
However, eradication of the virus in individuals with HIV has not been possible to date …
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection
DJ Colby, L Trautmann, S Pinyakorn, L Leyre… - Nature medicine, 2018 - nature.com
Antiretroviral therapy during the earliest stage of acute HIV infection (Fiebig I) might
minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after …
minimize establishment of a latent HIV reservoir and thereby facilitate viremic control after …
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial
L Bailón, A Llano, S Cedeño, T Escribà… - Nature Medicine, 2022 - nature.com
Abstract HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV)
vaccine immunogen designed to elicit cellular immune responses to HIV targets associated …
vaccine immunogen designed to elicit cellular immune responses to HIV targets associated …
The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies
G Namazi, JM Fajnzylber, E Aga… - The Journal of …, 2018 - academic.oup.com
Background HIV posttreatment controllers are rare individuals who start antiretroviral
therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of …
therapy (ART), but maintain HIV suppression after treatment interruption. The frequency of …
Why and where an HIV cure is needed and how it might be achieved
Despite considerable global investment, only 60% of people who live with HIV currently
receive antiretroviral therapy. The sustainability of current programmes remains unknown …
receive antiretroviral therapy. The sustainability of current programmes remains unknown …
Functional cure of HIV: the scale of the challenge
A variety of interventions to induce a functional cure of HIV are being explored, with the aim
being to allow patients to cease antiretroviral therapy (ART) for prolonged periods of time or …
being to allow patients to cease antiretroviral therapy (ART) for prolonged periods of time or …
Barriers and strategies to achieve a cure for HIV
9 years since the report of a cure for HIV after CC chemokine receptor type 5 Δ32 stem cell
transplantation, no other case of HIV cure has been reported, despite much research …
transplantation, no other case of HIV cure has been reported, despite much research …